Hybrid researcher Evotec has signed a deal with microbiomics biotech Second Genome to lend out its drug discovery capabilities in hopes of crafting treatments that harness the power of the gut.
WuXi PharmaTech, China's largest CRO, is positioning itself to cash in on the fervor over new immunotherapies for cancer, planning to build a U.S. facility devoted to manufacturing the newfangled cell therapies. Read more >>
CRO giant Icon dialed up its fourth-quarter revenue on the way to a big year, forecasting another leap in 2015. Read more >>
POPULAR COMMENT THREADS
Catalent is merging a few of its core business units in hopes of better focusing on getting its clients' drugs onto the market and pulling off smooth launches.
Contract drug developer Recipharm has inked a deal with Adroit Science to join forces in drug formulation.
U.K. contractor Ergomed has made Asian landfall, opening an office in Taiwan with eyes on forging traditional CRO deals and signing risk-sharing agreements with drugmakers.
Clinical trial service provider BioClinica is stretching out in the biopharma hotbed of Research Triangle Park, NC, opening a new operation to play a bigger role in drug development in the region.
When patients sign up for a clinical trial, how well do they understand the risks, requirements and restrictions that come with it? Icon, a global CRO that handles thousands of studies a year, is working with behavioral scientists at Carnegie Mellon University to study how investigators can improve the informed consent process.
Quintiles, the world's largest CRO, has reached out to startup Tute Genomics for access to its database of 8.5 billion annotations of genetic variants.
From Our Sister Sites
A new survey finds an astonishing "fat pet gap" in the U.S. According to the study, 58% of cats and 53% of dogs were overweight last year. Yet more than 90% of these pets' owners incorrectly identified their four-legged friends as normal weight.
The Obama Administration rolled out its 5-year plan to combat antibiotic-resistant bacteria on Thursday, and it was met with widespread disdain from critics who say it doesn't do enough to prevent livestock producers from using the drugs in ways that endanger both animal and human health.